235 related articles for article (PubMed ID: 36538748)
21. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla.
Inui S; Itami S
J Dermatol Sci; 2011 Jan; 61(1):1-6. PubMed ID: 21167691
[TBL] [Abstract][Full Text] [Related]
22. Androgenetic alopecia: pathogenesis and potential for therapy.
Ellis JA; Sinclair R; Harrap SB
Expert Rev Mol Med; 2002 Nov; 4(22):1-11. PubMed ID: 14585162
[TBL] [Abstract][Full Text] [Related]
23. Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro.
Rosette C; Rosette N; Mazzetti A; Moro L; Gerloni M
J Drugs Dermatol; 2019 Feb; 18(2):197-201. PubMed ID: 30811143
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms of androgenetic alopecia.
Trüeb RM
Exp Gerontol; 2002; 37(8-9):981-90. PubMed ID: 12213548
[TBL] [Abstract][Full Text] [Related]
25. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Olsen EA; Dunlap FE; Funicella T; Koperski JA; Swinehart JM; Tschen EH; Trancik RJ
J Am Acad Dermatol; 2002 Sep; 47(3):377-85. PubMed ID: 12196747
[TBL] [Abstract][Full Text] [Related]
26. The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.
Li L; Xu J
Clin Transl Oncol; 2023 Feb; 25(2):352-363. PubMed ID: 36203075
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.
Bao L; Zong H; Fang S; Zheng L; Li Y
J Dermatolog Treat; 2022 Feb; 33(1):483-493. PubMed ID: 32412314
[TBL] [Abstract][Full Text] [Related]
28. Androgenetic alopecia: an evidence-based treatment update.
Varothai S; Bergfeld WF
Am J Clin Dermatol; 2014 Jul; 15(3):217-30. PubMed ID: 24848508
[TBL] [Abstract][Full Text] [Related]
29. Dissolving microneedles for alopecia treatment.
Xiang H; Xu S; Zhang W; Xue X; Li Y; Lv Y; Chen J; Miao X
Colloids Surf B Biointerfaces; 2023 Sep; 229():113475. PubMed ID: 37536169
[TBL] [Abstract][Full Text] [Related]
30. Discovery of (2
Zhang W; Zhao S; Luo Y; Zhang Y; Feng Y; Tang F; Zhou X; Peng S; Fan Y; Xie S; Li H; Lai Q; Fu L; Luo Y; Pei S; Chen Z; Lu T; Tang R; Chen Y; Jiao Y
J Med Chem; 2024 Jan; 67(1):322-348. PubMed ID: 38128906
[TBL] [Abstract][Full Text] [Related]
31. Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia.
Faghihi G; Iraji F; Siadat AH; Saber M; Jelvan M; Hoseyni MS
J Cosmet Dermatol; 2022 Oct; 21(10):4447-4453. PubMed ID: 35152531
[TBL] [Abstract][Full Text] [Related]
32. Minoxidil Nanosuspension-Loaded Dissolved Microneedles for Hair Regrowth.
Hamed R; Alhadidi HFI
AAPS PharmSciTech; 2024 Apr; 25(4):75. PubMed ID: 38580793
[TBL] [Abstract][Full Text] [Related]
33. Androgenetic alopecia.
Piraccini BM; Alessandrini A
G Ital Dermatol Venereol; 2014 Feb; 149(1):15-24. PubMed ID: 24566563
[TBL] [Abstract][Full Text] [Related]
34. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
Suchonwanit P; Rojhirunsakool S; Khunkhet S
Lasers Med Sci; 2019 Dec; 34(9):1857-1864. PubMed ID: 30982177
[TBL] [Abstract][Full Text] [Related]
35. Androgenetic Alopecia in Gender Minority Patients.
Marks DH; Senna MM
Dermatol Clin; 2020 Apr; 38(2):239-247. PubMed ID: 32115134
[TBL] [Abstract][Full Text] [Related]
36. Microneedling in androgenetic alopecia; comparing two different depths of microneedles.
Faghihi G; Nabavinejad S; Mokhtari F; Fatemi Naeini F; Iraji F
J Cosmet Dermatol; 2021 Apr; 20(4):1241-1247. PubMed ID: 32897622
[TBL] [Abstract][Full Text] [Related]
37. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia.
Kim S; Eum J; Yang H; Jung H
J Control Release; 2019 Dec; 316():1-11. PubMed ID: 31689460
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility and validity of minoxidil response testing in androgenetic alopecia.
Goren A; Shapiro J; Roberts J; McCoy J; Desai N; Zarrab Z; Pietrzak A; Lotti T
Dermatol Ther; 2015; 28(1):13-6. PubMed ID: 25112173
[TBL] [Abstract][Full Text] [Related]
39. Topical cetirizine for treating androgenetic alopecia: A systematic review.
Chen X; Xiang H; Yang M
J Cosmet Dermatol; 2022 Nov; 21(11):5519-5526. PubMed ID: 35976065
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation.
Ghonemy S; Alarawi A; Bessar H
J Dermatolog Treat; 2021 Mar; 32(2):236-241. PubMed ID: 31403367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
